Humacyte

06/18/2026

We hope you had the opportunity to connect with our team and learn more about Symvess® acellular tissue engineered vessel-tyod at the TOUCHPOINT Hands-on / SIM Lab, The Women in Vascular Surgery Forum, or our exhibit booth at the VAM 2026 conference. We truly appreciate the engagement and interest in Symvess—our first-in-class, universally implantable, bioengineered human vessel indicated for urgent extremity arterial injury.

We are excited to continue supporting you and your teams in learning more about this innovative repair option, and we sincerely value the thoughtful questions and discussions.

VAM 2026 offered so many valuable educational opportunities. Contact us to keep the discussion going. We look forward to connecting soon!

Contact Us Here: https://symvess.com/contact-us/

Learn more about Symvess here: https://bit.ly/atev_prod_huma

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://bit.ly/4dl5tuL

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

BOXED WARNING: GRAFT FAILURE: Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved. US-SYM-000349

$HUMA

06/16/2026

🚨 New Clinical Milestone from Humacyte in AV Access!

Humacyte recently announced interim Phase 3 (V012) results in female dialysis access patients. The ATEV met V012’s primary endpoint and showed superior catheter-free days (p=0.00070) compared with autologous arteriovenous fistula (AVF), the current standard of care. Women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received an AVF.

The data reinforce the potential to improve outcomes in a patient population with a high unmet need.

This major milestone marks the end of the Phase 3 study enrollment and will support Humacyte’s plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026.

Full results were presented June 11 at the Society for Vascular Surgery Annual Meeting in Boston during the Women’s Health Seminar.

For more details, read the full press release here: 🔗 https://bit.ly/3SaQzSc

Learn more about Humacyte at www.humacyte.com

$HUMA

Trademarks are the property of Humacyte Global, Inc.
© 2026 Humacyte Global, Inc. All rights reserved.

06/15/2026

June is Men’s Health Month, an important time to focus on conditions that quietly impact long term health—starting with vascular disease.

Peripheral artery disease (PAD) affects millions of Americans and can quietly lead to serious outcomes like mobility loss, cardiovascular events, and even amputation. Each year, about 150,000 nontraumatic lower‑extremity amputations occur in the United States, with men representing the majority of patients.1,2
For men with advanced PAD, treatment can be especially challenging. Clinical studies show that 15–45% of patients with severe PAD or chronic limb threatening ischemia lack a suitable saphenous vein for use in bypassing the diseased artery, limiting traditional surgical options.3,4

Raising awareness of PAD and encouraging earlier conversations about vascular health can make a real difference—for long term limb and life outcomes. This Men’s Health Month, Humacyte encourages continued education, early PAD recognition, and informed conversations around vascular health—because circulation plays a critical role in long term limb and life outcomes.

Learn more about Humacyte and our groundbreaking science and vascular innovations at https://humacyte.com

References:
1. Creager MA, Matsush*ta K, Arya S, et al. Reducing nontraumatic lower extremity amputations by 20% by 2030: a policy statement from the American Heart Association. Circulation. 2021;143:e108‑e124.
2. Gill SS, Chaudhary M, Zakrison TL. Nontraumatic amputations in the United States—an urgent matter of equity. JAMA Surg. 2024;159(1):76‑77. doi:10.1001/jamasurg.2023.5523
3. Garbaisz D, Osztrogonácz P, Boros AM, Hidi L, Sótonyi P, Szeberin Z. Comparison of arterial and venous allograft bypass in chronic limb‑threatening ischemia. PLoS One. 2022;17(10):e0275628. doi:10.1371/journal.pone.0275628
4. Taylor LM Jr, Edwards JM, Brant B, Phinney ES, Porter JM. Autogenous reversed vein bypass for lower extremity ischemia in patients with absent or inadequate greater saphenous vein. Am J Surg. 1987;153(5):505‑510. doi:10.1016/0002‑9610(87)90803‑8

Humacyte is a trademark and property of Humacyte Global, Inc. © 2026 Humacyte Global Inc. All Rights Reserved.

06/11/2026

Join Us Tonight to Learn More !

There are clear unmet needs in AV Access for Women. (1,2)

Join leaders in vascular innovation at the Women in Vascular Surgery Forum, sponsored by Humacyte. The team will share recent Interim Results from the Women-Only Study in AV Access.

Thursday, June 11, 2026
7:00–8:30 PM EST
Sheraton, 2nd Floor, Back Bay C

Speakers:
Young Erben, MD, FACS
Associate Professor of Surgery
Mayo Clinic in Jacksonville, FL

Laura Niklason, MD, PhD
Founder, President & CEO
Humacyte Global, Inc.

Be part of the conversation advancing care for women.

ALSO VISIT our MEDICAL INFORMATION TEAM at SVS - BOOTH #307

Learn more about Humacyte here: https://humacyte.com

For uses other than the FDA approval in the extremity vascular injury indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Sources: 1. USRDS 2025 Annual Data. 2. Coker et al., The Journal of Vascular Access, 2018.

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global, Inc. All Rights Reserved.

$HUMA

06/11/2026

Join us at the Hands-On Simulation lab!
The Humacyte® team is proud to host a Hands on SIM Lab featuring Symvess® acellular tissue engineered vessel-type (ATEV)—and it’s happening today and tomorrow.

During the Society for Vascular Surgery VAM 2026 TOUCHPOINT Hands on / SIM Lab, participants can practice handling and implantation techniques, perform anastomosis, and apply proper clamping and procedural methods, with support from the Humacyte team throughout the session.

SIM Lab Location: Hynes Convention Center, Second Level, Auditorium (in the Exhibit Hall)
• Thursday, June 11: 10:15 AM – 6:15 PM
• Friday, June 12: 9:30 AM – 2:00 PM

While you’re here, stop by Booth 307 to connect with the Humacyte team and continue the conversation.

Contact Us Here: https://symvess.com/contact-us/

Learn more about Symvess here: https://bit.ly/atev_prod_huma

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://bit.ly/4dl5tuL

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

BOXED WARNING: GRAFT FAILURE: Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Trademarks are property of Humacyte Global, Inc
Other trademarks are property of their respective owners.
© 2026 Humacyte Global Inc. All Rights Reserved. US-SYM-000348

$HUMA

06/08/2026

There are clear unmet needs in AV Access for Women. (1,2)

Join leaders in vascular innovation at the Women in Vascular Surgery Forum, sponsored by Humacyte. The team will share recent Interim Results from the Women-Only Study in AV Access.

Thursday, June 11, 2026
7:00–8:30 PM EST
Sheraton, 2nd Floor, Back Bay C

Speakers:
Young Erben, MD, FACS
Associate Professor of Surgery
Mayo Clinic in Jacksonville, FL

Laura Niklason, MD, PhD
Founder, President & CEO
Humacyte Global, Inc.

Be part of the conversation advancing care for women.

ALSO VISIT our MEDICAL INFORMATION TEAM at SVS - BOOTH #307

Learn more about Humacyte here: https://humacyte.com

For uses other than the FDA approval in the extremity vascular injury indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Sources: 1. USRDS 2025 Annual Data. 2. Coker et al., The Journal of Vascular Access, 2018.

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global, Inc. All Rights Reserved.

$HUMA

06/05/2026

Women with AV Access face clear unmet needs.
• 50% fail AVF maturation (vs. 37% in men)1
• 30% use catheter for hemodialysis (vs. 24% in men)1
• 2× higher risk of catheter dysfunction2
• 1 in 2 use infection-prone access – catheters and synthetic grafts1

Be part of the conversation advancing care for women.
VISIT our MEDICAL INFORMATION TEAM at SVS - BOOTH #307

Learn more about Humacyte here: www.humacyte.com

For uses other than the FDA approval in the extremity vascular injury indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

REFERENCES: 1. USRDS 2025 Annual Data. 2. Coker et al., The Journal of Vascular Access, 2018.

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global, Inc. All Rights Reserved.

$HUMA

06/05/2026

We’re excited to be at VAM 2026 and proud to host a Hands on/SIM Lab featuring Symvess® acellular tissue engineered vessel-tyod.

During the VAM 2026 Hands on/SIM Lab, participants can practice handling and implantation techniques, perform anastomosis, and apply proper clamping and procedural methods—all supported by the Humacyte team throughout the session.

SIM Lab Location: Hynes Convention Center, Second Level, Auditorium
• Thursday, June 11: 10:15 AM – 6:15 PM
• Friday, June 12: 9:30 AM – 2:00 PM

Be sure to also stop by Booth 307 to connect with the Humacyte team and continue the conversation.

Contact Us Here: https://symvess.com/contact-us/

Learn more about Symvess here: https://bit.ly/atev_prod_huma
PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://bit.ly/4dl5tuL

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

BOXED WARNING: GRAFT FAILURE: Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Trademarks are property of Humacyte Global, Inc
Other trademarks are property of their respective owners.
© 2026 Humacyte Global, Inc. All Rights Reserved. US-SYM-000348

$HUMA

06/04/2026

Join us at Booth 307 at the SVS Vascular Annual Meeting, taking place June 10–13. The Humacyte team is ready to connect, walk you through the technology, and answer your questions about Symvess, a first-in-class, universally implantable, bioengineered human vessel for extremity vascular arterial injury replacement and repair. Both our sales and medical information teams will be there to answer all your questions.

Learn more about Symvess here: https://bit.ly/atev_prod_huma

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://bit.ly/4dl5tuL

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

BOXED WARNING: GRAFT FAILURE: Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved. US-SYM-000348

$HUMA
REFERENCES: 1. Symvess U.S. Prescribing Information. Durham, NC. Humacyte Global, Inc.

06/01/2026

Humacyte has recently announced that Symvess® acellular tissue engineered vessel-tyod is now under contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs. This “Surgical Implant- Next Generation” contract will help expand access to this first-in-class bioengineered blood vessel across more than 170 VA hospitals nationwide.

This milestone reflects rigorous clinical and value-based review and marks an important step forward in delivering innovative vascular care to the veterans.

For more details read the full press release here: 🔗 https://bit.ly/4ed8vE8

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://bit.ly/4dl5tuL

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved.

$HUMA